Nasal vaccine platform Leverage Vivaldi’s Delta NS1 vector and self-adjuvanting nasal spray approach to position partnerships or contract work in intranasal vaccine development, especially for respiratory viruses and rapid-onset immunity.

Universal flu focus Target collaborations around the DeltaFLU universal influenza vaccine and its transmission-blocking potential, appealing to health authorities and pharma partners seeking broad-coverage influenza solutions.

Clinical stage opportunity With DeltaFLU in Phase 2 and Delta-19 entering trials, pursue co-development, licensing, or funding discussions with biotech investors and large sponsors looking to back late-stage vaccine candidates.

Public funding interest Capitalize on recent grants and backing from entities like Flu Lab to showcase government and NGO funding credibility, opening doors for further grant-supported collaborations and milestone-driven deals.

Strategic partnerships Position Vivaldi as a nimble, specialized partner for contract development and manufacturing of nasal vaccines, appealing to larger CROs or CDMOs seeking strategic alliances in respiratory vaccine programs.